N
MRNA icon

Natixis’s Moderna MRNA Stock Holding History

Natixis’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000,000
Closed -$29.5M – 1250
2025
Q4 		$29.5M Sell
1,000,000
-600,000
-38% -$16.3M 0.1% 143
2025
Q3 		$41.3M Buy
1,600,000
+1,000,000
+167% +$27.9M 0.19% 89
2025
Q2 		$16.6M Buy
+600,000
New +$15.8M 0.07% 171

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Natixis's MRNA Position: Q2 2026 in Review

Natixis opened a new position in Moderna (MRNA) in Q2 2026: 66,370 shares worth $4.65M. The stake represents 0.02% of the portfolio and ranks #453 among its holdings. This is a return to the name: Natixis previously reported a position in MRNA as recently as Q4 2025.

Natixis first reported a position in MRNA in Q1 2019 and has held it in 23 quarters since. The position peaked at $125M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Natixis held 66,370 shares of Moderna worth $4.65M as of Q2 2026.
  • Moderna was a new Natixis position in Q2 2026.
  • Moderna made up 0.02% of Natixis's portfolio in Q2 2026, its #453 holding.
  • Natixis first reported a position in Moderna in Q1 2019 and has held it in 23 quarters since.
  • Natixis's Moderna position peaked at $125M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.